Format

Send to

Choose Destination
Am J Hematol. 2019 Apr 3. doi: 10.1002/ajh.25484. [Epub ahead of print]

Optimizing survival outcomes with post-remission therapy in acute myeloid leukemia.

Author information

1
Department of Hematology, Stanford University School of Medicine, Stanford, California.
2
Princess Margaret Cancer Centre, Toronto, Ontario, Canada.
3
Department of Leukemia, MD Anderson Cancer Center, Houston, Texas.
4
University of California Davis Comprehensive Cancer Center, Sacramento, California.
5
University of Colorado School of Medicine, Aurora, Colorado.

Abstract

Optimization of post-remission therapies to maintain complete remission and prevent relapse is a major challenge in treating patients with acute myeloid leukemia (AML). Monitoring patients for measurable residual disease (MRD) is helpful to identify those at risk for relapse. Hypomethylating agents are being investigated as post-remission therapy. Identification of recurrent genetic alterations that drive disease progression has enabled the design of new, personalized approaches to therapy for patients with AML. Emerging data suggest that targeted post-remission therapy, alone or in combination with chemotherapy, may improve outcomes. Results of ongoing clinical trials will further define potential clinical benefits.

PMID:
30945331
DOI:
10.1002/ajh.25484

Supplemental Content

Loading ...
Support Center